Shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) shot up 2.4% on Wednesday . The company traded as high as $0.51 and last traded at $0.43. 5,667 shares were traded during mid-day trading, a decline of 99% from the average session volume of 822,020 shares. The stock had previously closed at $0.42.
Separately, HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Eyegate Pharmaceuticals in a research note on Wednesday, September 5th.
The company has a market cap of $13.47 million, a P/E ratio of -0.40 and a beta of 3.53.
Eyegate Pharmaceuticals Company Profile (NASDAQ:EYEG)
EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.
See Also: Why is insider trading harmful?
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.